Latest Insider Transactions at Scholar Rock Holding Corp (SRRK)
This section provides a real-time view of insider transactions for Scholar Rock Holding Corp (SRRK). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Scholar Rock Holding Corp to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Scholar Rock Holding Corp's insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 24
2025
|
Erin Moore Interim PFO and PAO |
SELL
Open market or private sale
|
Direct |
13,564
-14.1%
|
$447,612
$33.12 P/Share
|
|
Mar 24
2025
|
Erin Moore Interim PFO and PAO |
BUY
Exercise of conversion of derivative security
|
Direct |
13,564
+6.79%
|
$244,152
$18.69 P/Share
|
|
Mar 24
2025
|
Tracey Sacco Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
6,500
-4.22%
|
$214,500
$33.3 P/Share
|
|
Mar 24
2025
|
Tracey Sacco Chief Commercial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+6.01%
|
$50,000
$10.0 P/Share
|
|
Mar 17
2025
|
Katie Peng |
SELL
Open market or private sale
|
Direct |
1,006
-3.21%
|
$34,204
$34.42 P/Share
|
|
Mar 10
2025
|
Edward H Myles COO & CFO |
SELL
Open market or private sale
|
Direct |
142,292
-32.7%
|
$4,980,220
$35.34 P/Share
|
|
Mar 10
2025
|
Edward H Myles COO & CFO |
BUY
Exercise of conversion of derivative security
|
Direct |
112,897
+9.53%
|
$1,354,764
$12.5 P/Share
|
|
Mar 10
2025
|
Tracey Sacco Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
27,855
+27.55%
|
-
|
|
Mar 10
2025
|
Junlin Ho GENERAL COUNSEL |
BUY
Grant, award, or other acquisition
|
Direct |
32,145
+12.68%
|
-
|
|
Mar 10
2025
|
Jay T. Backstrom CHIEF EXECUTIVE OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
113,570
+21.07%
|
-
|
|
Mar 10
2025
|
Jing L. Marantz CHIEF MEDICAL OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
34,285
+25.25%
|
-
|
|
Mar 10
2025
|
Caryn Parlavecchio CHRO |
BUY
Grant, award, or other acquisition
|
Direct |
23,570
+12.58%
|
-
|
|
Mar 10
2025
|
Mo Qatanani CHIEF SCIENTIFIC OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
32,145
+18.33%
|
-
|
|
Feb 19
2025
|
Mo Qatanani CHIEF SCIENTIFIC OFFICER |
SELL
Open market or private sale
|
Direct |
68,510
-14.54%
|
$2,534,870
$37.5 P/Share
|
|
Feb 19
2025
|
Mo Qatanani CHIEF SCIENTIFIC OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
48,308
+6.83%
|
$434,772
$9.56 P/Share
|
|
Feb 18
2025
|
Mo Qatanani CHIEF SCIENTIFIC OFFICER |
SELL
Open market or private sale
|
Direct |
4,135
-3.05%
|
$148,860
$36.83 P/Share
|
|
Feb 18
2025
|
Caryn Parlavecchio CHRO |
SELL
Open market or private sale
|
Direct |
5,296
-3.64%
|
$190,656
$36.83 P/Share
|
|
Feb 18
2025
|
Edward H Myles COO & CFO |
SELL
Open market or private sale
|
Direct |
7,809
-5.26%
|
$281,124
$36.83 P/Share
|
|
Feb 18
2025
|
Junlin Ho GENERAL COUNSEL |
SELL
Open market or private sale
|
Direct |
5,742
-2.94%
|
$206,712
$36.83 P/Share
|
|
Feb 18
2025
|
Jay T. Backstrom CHIEF EXECUTIVE OFFICER |
SELL
Open market or private sale
|
Direct |
18,372
-5.56%
|
$661,392
$36.83 P/Share
|
|
Jan 16
2025
|
Junlin Ho GENERAL COUNSEL |
SELL
Open market or private sale
|
Direct |
9,039
-4.43%
|
$397,716
$44.2 P/Share
|
|
Jan 16
2025
|
Edward H Myles COO & CFO |
SELL
Open market or private sale
|
Direct |
12,539
-7.78%
|
$551,716
$44.2 P/Share
|
|
Jan 16
2025
|
Caryn Parlavecchio CHRO |
SELL
Open market or private sale
|
Direct |
6,434
-4.23%
|
$283,096
$44.2 P/Share
|
|
Jan 16
2025
|
Mo Qatanani CHIEF SCIENTIFIC OFFICER |
SELL
Open market or private sale
|
Direct |
7,347
-5.15%
|
$323,268
$44.2 P/Share
|
|
Jan 16
2025
|
Tracey Sacco Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
3,890
-7.89%
|
$171,160
$44.2 P/Share
|
|
Jan 16
2025
|
Jing L. Marantz CHIEF MEDICAL OFFICER |
SELL
Open market or private sale
|
Direct |
5,655
-7.76%
|
$248,820
$44.2 P/Share
|
|
Jan 16
2025
|
Jay T. Backstrom CHIEF EXECUTIVE OFFICER |
SELL
Open market or private sale
|
Direct |
22,308
-6.33%
|
$981,552
$44.2 P/Share
|
|
Dec 10
2024
|
Invus Public Equities, L.P. |
SELL
Open market or private sale
|
Direct |
1,600,000
-14.75%
|
$65,600,000
$41.65 P/Share
|
|
Nov 25
2024
|
Invus Public Equities, L.P. |
SELL
Open market or private sale
|
Direct |
409,433
-0.74%
|
$15,967,887
$39.34 P/Share
|
|
Nov 25
2024
|
Jing L. Marantz CHIEF MEDICAL OFFICER |
SELL
Open market or private sale
|
Direct |
6,375
-2.06%
|
$248,625
$39.49 P/Share
|
|
Nov 25
2024
|
Jing L. Marantz CHIEF MEDICAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
6,375
+7.45%
|
$51,000
$8.59 P/Share
|
|
Nov 22
2024
|
Jing L. Marantz CHIEF MEDICAL OFFICER |
SELL
Open market or private sale
|
Direct |
2,145
-2.86%
|
$64,350
$30.01 P/Share
|
|
Nov 22
2024
|
Jing L. Marantz CHIEF MEDICAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
2,145
+2.78%
|
$17,160
$8.59 P/Share
|
|
Nov 12
2024
|
Michael Gilman |
BUY
Bona fide gift
|
Direct |
37,459
+42.37%
|
-
|
|
Nov 12
2024
|
Michael Gilman |
SELL
Bona fide gift
|
Indirect |
37,459
-100.0%
|
-
|
|
Nov 11
2024
|
Jing L. Marantz CHIEF MEDICAL OFFICER |
SELL
Open market or private sale
|
Direct |
2,105
-2.81%
|
$63,150
$30.0 P/Share
|
|
Nov 11
2024
|
Jing L. Marantz CHIEF MEDICAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
2,105
+2.73%
|
$16,840
$8.59 P/Share
|
|
Oct 08
2024
|
Edward H Myles COO & CFO |
SELL
Open market or private sale
|
Direct |
37,187
-18.76%
|
$1,264,358
$34.9 P/Share
|
|
Oct 08
2024
|
Edward H Myles COO & CFO |
BUY
Exercise of conversion of derivative security
|
Direct |
37,187
+15.79%
|
$371,870
$10.0 P/Share
|
|
Oct 07
2024
|
Edward H Myles COO & CFO |
SELL
Open market or private sale
|
Direct |
206,240
-18.28%
|
$5,568,480
$27.19 P/Share
|
|
Oct 07
2024
|
Edward H Myles COO & CFO |
SELL
Exercise of conversion of derivative security
|
Direct |
206,240
-35.96%
|
$2,681,120
$13.83 P/Share
|
|
Oct 07
2024
|
Tracey Sacco Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
30,000
-19.6%
|
$750,000
$25.91 P/Share
|
|
Oct 07
2024
|
Tracey Sacco Chief Commercial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
30,000
+27.45%
|
$300,000
$10.0 P/Share
|
|
Oct 07
2024
|
Srinivas Akkaraju |
SELL
Open market or private sale
|
Indirect |
1,175,713
-6.11%
|
$35,271,390
$30.0 P/Share
|
|
Oct 07
2024
|
Jing L. Marantz CHIEF MEDICAL OFFICER |
SELL
Open market or private sale
|
Direct |
109,375
-24.77%
|
$2,953,125
$27.29 P/Share
|
|
Oct 07
2024
|
Jing L. Marantz CHIEF MEDICAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
109,375
+37.51%
|
$875,000
$8.59 P/Share
|
|
Sep 16
2024
|
Mo Qatanani CHIEF SCIENTIFIC OFFICER |
SELL
Open market or private sale
|
Direct |
1,936
-1.34%
|
$15,488
$8.58 P/Share
|
|
Aug 16
2024
|
Caryn Parlavecchio CHRO |
SELL
Open market or private sale
|
Direct |
1,451
-0.95%
|
$13,059
$9.33 P/Share
|
|
Jun 27
2024
|
Kristina Burow |
BUY
Grant, award, or other acquisition
|
Direct |
13,500
+41.75%
|
-
|
|
Jun 27
2024
|
Katie Peng |
BUY
Grant, award, or other acquisition
|
Direct |
4,500
+12.56%
|
-
|